STAT

Opinion: As the world prepares to fight Lassa fever, the interests of pregnant women must be part of the planning

The interests of pregnant women weren't included in thinking about making and deploying a vaccine against Ebola. We can't make that same mistake with Lassa fever.
A transmission electron microscope reveals the size and shape of the virus that causes Lassa fever.

As health officials work to contain the continuing outbreak of Ebola in the Democratic Republic of Congo, lessons from that crisis can be applied to more equitably battle Lassa fever, another deadly infectious disease.

As 2019 begins, the Ebola outbreak in the DRC is a of tragic proportions. This outbreak, the second largest in history, disproportionally affects women of childbearing potential. Unfortunately, the only available Ebola vaccine has characteristics that make it problematic for use in women who are pregnant. Although they are at high risk of becoming infected and dying,

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About A GLP-1 Side Effect, U.K. Clinical Trial Transparency, And More
A new study links GLP-1 drugs like Ozempic to a higher risk of aspiration pneumonia — a lung infection caused by food breathed into the lungs — after endoscopies.
STAT1 min read
STAT+: Medicare Expected To Negotiate Obesity Drug Prices Soon, New Analysis Predicts
Medicare will likely choose the obesity drug semaglutide for price negotiation “within the next few years,” according to a new analysis.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About An AstraZeneca Deal, A WHO Pandemic Pact, And More
AstraZeneca agreed to acquire Fusion Pharmaceuticals in a deal worth more than $2 billion, picking up a company focused on targeted radiation therapies for cancer.

Related Books & Audiobooks